Results 181 to 190 of about 371,513 (350)
The Role of miRNAs in Chicken Immune Regulation and Prospects for Disease‐Resistant Breeding
A schematic workflow illustrating the screening of disease‐resistant miRNAs and the generation of miRNA‐based disease‐resistant chickens via PGC‐mediated germline genome editing. ABSTRACT MicroRNAs (miRNAs) are emerging as pivotal regulators of the immune system, playing a decisive role in shaping disease resistance in chicken.
Qiangzhou Wang +10 more
wiley +1 more source
Bullous Systemic Lupus Erythematosus As the Initial Presentation of Systemic Lupus Erythematosus. [PDF]
Kydyralieva C.
europepmc +1 more source
Anifrolumab for refractory chilblain lupus erythematosus. [PDF]
Bulosan H +3 more
europepmc +1 more source
Mucosal‐Associated Invariant T Cells in Rheumatic Diseases
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek +7 more
wiley +1 more source
Polypharmacy in Adults With Systemic Lupus Erythematosus. [PDF]
Yang J +9 more
europepmc +1 more source
Autoantibody Response Toward Chromatin in Patients With Juvenile Idiopathic Arthritis
Objective Patients with juvenile idiopathic arthritis (JIA) frequently exhibit antinuclear antibodies (ANAs), but the specific antigen target recognized by them and the presence of additional autoantibody specificities in patients with JIA remains elusive.
Viola Pitkänen +13 more
wiley +1 more source
Rapid clinical response in refractory discoid lupus erythematosus treated with anifrolumab. [PDF]
Ramos J, Leme H, Magarreiro-Silva A.
europepmc +1 more source
Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman +2 more
wiley +1 more source

